One binding partner of FOXO3 is the tumor protein TP53/p53 which is mutated in over 50% of cancer types.20 In NB, however, mutations of TP53 are rare at diagnosis (less than 2% of patients), but frequent loss of function is observed in relapsed tumors.21 FOXO3 and TP53 share numerous target genes such as CDKN1/P21CIP1, GADD45A or BBC3/PUMA; hence, they are involved in the same cellular processes like cell-cycle-arrest, DNA-damage-repair and apoptosis.22, 23, 24, 25. This evidence concerns the gene CDKN1A and cancer.